Historical Valuation
Spero Therapeutics Inc (SPRO) is now in the Overvalued zone, suggesting that its current forward PS ratio of 18.98 is considered Overvalued compared with the five-year average of -2.24. The fair price of Spero Therapeutics Inc (SPRO) is between 0.35 to 2.45 according to relative valuation methord. Compared to the current price of 2.55 USD , Spero Therapeutics Inc is Overvalued By 4.15%.
Relative Value
Fair Zone
0.35-2.45
Current Price：2.55
4.15%
Overvalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Spero Therapeutics Inc (SPRO) has a current Price-to-Book (P/B) ratio of 4.99. Compared to its 3-year average P/B ratio of 1.68 , the current P/B ratio is approximately 197.64% higher. Relative to its 5-year average P/B ratio of 2.31, the current P/B ratio is about 116.68% higher. Spero Therapeutics Inc (SPRO) has a Forward Free Cash Flow (FCF) yield of approximately -20.90%. Compared to its 3-year average FCF yield of -15.32%, the current FCF yield is approximately 36.45% lower. Relative to its 5-year average FCF yield of -39.38% , the current FCF yield is about -46.92% lower.
P/B
Median3y
1.68
Median5y
2.31
FCF Yield
Median3y
-15.32
Median5y
-39.38
Competitors Valuation Multiple
AI Analysis for SPRO
The average P/S ratio for SPRO competitors is 3.16, providing a benchmark for relative valuation. Spero Therapeutics Inc Corp (SPRO.O) exhibits a P/S ratio of 18.98, which is 500% above the industry average. Given its robust revenue growth of -59.60%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for SPRO
1Y
3Y
5Y
Market capitalization of SPRO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of SPRO in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is SPRO currently overvalued or undervalued?
Spero Therapeutics Inc (SPRO) is now in the Overvalued zone, suggesting that its current forward PS ratio of 18.98 is considered Overvalued compared with the five-year average of -2.24. The fair price of Spero Therapeutics Inc (SPRO) is between 0.35 to 2.45 according to relative valuation methord. Compared to the current price of 2.55 USD , Spero Therapeutics Inc is Overvalued By 4.15% .
What is Spero Therapeutics Inc (SPRO) fair value?
SPRO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Spero Therapeutics Inc (SPRO) is between 0.35 to 2.45 according to relative valuation methord.
How does SPRO's valuation metrics compare to the industry average?
The average P/S ratio for SPRO's competitors is 3.16, providing a benchmark for relative valuation. Spero Therapeutics Inc Corp (SPRO) exhibits a P/S ratio of 18.98, which is 500.00% above the industry average. Given its robust revenue growth of -59.60%, this premium appears unsustainable.
What is the current P/B ratio for Spero Therapeutics Inc (SPRO) as of Jan 10 2026?
As of Jan 10 2026, Spero Therapeutics Inc (SPRO) has a P/B ratio of 4.99. This indicates that the market values SPRO at 4.99 times its book value.
What is the current FCF Yield for Spero Therapeutics Inc (SPRO) as of Jan 10 2026?
As of Jan 10 2026, Spero Therapeutics Inc (SPRO) has a FCF Yield of -20.90%. This means that for every dollar of Spero Therapeutics Inc’s market capitalization, the company generates -20.90 cents in free cash flow.
What is the current Forward P/E ratio for Spero Therapeutics Inc (SPRO) as of Jan 10 2026?
As of Jan 10 2026, Spero Therapeutics Inc (SPRO) has a Forward P/E ratio of 4.92. This means the market is willing to pay $4.92 for every dollar of Spero Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Spero Therapeutics Inc (SPRO) as of Jan 10 2026?
As of Jan 10 2026, Spero Therapeutics Inc (SPRO) has a Forward P/S ratio of 18.98. This means the market is valuing SPRO at $18.98 for every dollar of expected revenue over the next 12 months.